<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119687</url>
  </required_header>
  <id_info>
    <org_study_id>FX201-2019-001</org_study_id>
    <nct_id>NCT04119687</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part study will be conducted in male and female patients, 30 - 80 years of age with&#xD;
      painful OA of the index knee with Kellgren-Lawrence (K-L) Grade 2, 3 or 4.&#xD;
&#xD;
      Part 1 - Single Ascending Dose (SAD) Phase: Up to three ascending doses of FX201 will be&#xD;
      tested in cohorts of 5-8 patients. Each patient will only receive one injection of FX201. An&#xD;
      independent Data Monitoring Committee (DMC) will review safety and guide the conduct of the&#xD;
      study.&#xD;
&#xD;
      Part 2 - Expansion Phase: Up to an additional 35 patients will be enrolled at each dose level&#xD;
      reviewed by the DMC. Each patient will only receive one injection of FX201.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two-part study will be conducted in male and female patients, 30 - 80 years of age with&#xD;
      painful OA of the index knee with Kellgren-Lawrence (K-L) Grade 2, 3 or 4.&#xD;
&#xD;
      Part 1 - SAD Phase: Up to three ascending doses of FX201 (low dose, mid dose and high dose)&#xD;
      will be tested in cohorts of 5-8 patients. Each patient will only receive one injection of&#xD;
      FX201. A maximum of 24 patients will be enrolled (range 15 to 24).&#xD;
&#xD;
      When a minimum of 4 weeks have elapsed since the last patient of the current cohort has been&#xD;
      treated, all safety data will be collected and reviewed by an independent Data Monitoring&#xD;
      Committee (DMC). After evaluating cohort safety data, the DMC will evaluate continuing the&#xD;
      trial and initiating treatment in the next dosing cohort as well as expanding enrollment in&#xD;
      dose level(s).&#xD;
&#xD;
      Part 2 - Expansion Phase: After the DMC has met to review safety data from each Cohort and&#xD;
      has recommended expanding dose level(s), enrollment slots for dose levels reviewed by the DMC&#xD;
      will be opened. A maximum of 105 patients [up to an additional 35 patients per dose level (up&#xD;
      to 20 FX201 alone and up to 15 FX201 with IA methylprednisolone 40 mg/mL pre-treatment)].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">December 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 - Open-Label, Single Ascending Dose Phase Part 2 - Open-Label, Expansion Phase to enroll additional patients in DMC-cleared dose levels by sequential assignment against a pre-defined randomized list</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure: Incidence of treatment emergent adverse events after a single intra-articular (IA) injection of FX201 (safety and tolerability)</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Incidence of treatment emergent adverse events after a single intra-articular (IA) injection of FX201</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measure: Characterization of the systemic biodistribution of FX201 as seen through the percentage of patients positive for FX201 at Baseline, Day 1, Day 2, Week 1, Week 2, Week 3, and Week 4</measure>
    <time_frame>Baseline, Day 1, Day 2, Week 1, Week 2, Week 3, Week 4</time_frame>
    <description>The percentage of patients positive for FX201 at select timepoints</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Low Dose FX201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single low dose FX201 injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose FX201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single mid dose FX201 injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose FX201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single high dose FX201 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FX201</intervention_name>
    <description>FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.</description>
    <arm_group_label>High Dose FX201</arm_group_label>
    <arm_group_label>Low Dose FX201</arm_group_label>
    <arm_group_label>Mid Dose FX201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
          -  Male or female 30 to 80 years of age, inclusive, on the day of enrollment (Day 1)&#xD;
&#xD;
          -  Body mass index (BMI) â‰¤ 40 kilograms per meters squared (kg/m2)&#xD;
&#xD;
          -  Clinical diagnosis of OA of the knee on the American College of Rheumatology criteria&#xD;
             (Altman, 1986) with radiologic evidence of OA (K-L Grade 2 or 3 for SAD Phase Cohort A&#xD;
             and K-L Grade 2, 3 or 4 for SAD Phase Cohorts B and C and the Expansion Phase) at the&#xD;
             index joint at the screening visit&#xD;
&#xD;
          -  Moderate pain in the index joint&#xD;
&#xD;
          -  Failed two or more types of conservative therapy for index knee osteoarthritis (e.g.,&#xD;
             structured exercise programs, topical or oral non-steroidal anti-inflammatory&#xD;
             therapies); or failed one prior type of conservative therapy and at least one prior&#xD;
             index knee IA treatment (corticosteroid or hyaluronic acid)&#xD;
&#xD;
          -  Sexually active females and males agree to use highly effective methods of&#xD;
             contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,&#xD;
             or arthritis associated with inflammatory bowel disease&#xD;
&#xD;
          -  History of or current infection in the index knee joint&#xD;
&#xD;
          -  Inability to undergo Magnetic Resonance Imaging (MRI) due to presence of surgical&#xD;
             hardware or other foreign body in the index knee&#xD;
&#xD;
          -  Unstable index knee joint (e.g., torn anterior cruciate ligament, etc.) within 12&#xD;
             months of Screening&#xD;
&#xD;
          -  Any IA drug/biologic use within 6 months of Screening or 5 half-lives (whichever is&#xD;
             longer) (e.g., IA corticosteroid, IA hyaluronic acid, platelet rich plasma injection,&#xD;
             stem cells, prolotherapy and amniotic fluid injection, etc.)&#xD;
&#xD;
          -  Cold or radiofrequency nerve ablation of the index knee within 12 months of Screening&#xD;
&#xD;
          -  Arthroscopic or open surgery on the index knee within 12 months of Screening or&#xD;
             planned/anticipated surgery on the index knee for the study period&#xD;
&#xD;
          -  Anticipated major surgery during the study period&#xD;
&#xD;
          -  Laboratory values that meet exclusion criteria&#xD;
&#xD;
          -  ECG abnormality at Screening or Baseline judged clinically significant&#xD;
&#xD;
          -  Use of immunomodulators, immunosuppressive, or chemotherapeutic agents within 5 years&#xD;
             of Screening&#xD;
&#xD;
          -  Use of any other investigational drug, biologic or device within 3 months of Screening&#xD;
&#xD;
          -  Any systemic or local bacterial or viral infection requiring IV antibiotics or&#xD;
             antivirals within 4 weeks of Screening or oral antibiotics or antivirals within 2&#xD;
             weeks of Screening&#xD;
&#xD;
          -  Known allergy or sensitivity to methylprednisolone&#xD;
&#xD;
          -  Any other clinically significant acute or chronic medical conditions (e.g., bleeding&#xD;
             disorder) that, in the judgment of the Investigator, would preclude the use of an IA&#xD;
             injection or that could compromise patient safety, limit the patient's ability to&#xD;
             complete the study, and/or compromise the objectives of the study&#xD;
&#xD;
        Note: Other protocol defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Andrews, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corrinne Lauze</last_name>
    <phone>781-305-7124</phone>
    <email>clauze@flexiontherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brianna Fidler</last_name>
    <phone>781-305-7535</phone>
    <email>bfidler@flexiontherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Jaffe, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Melissa Martin</last_name>
      <phone>205-327-1077</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Gimbel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Briana Hernandez</last_name>
      <phone>602-773-3031</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Research Institute, LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Stolarski</last_name>
    </contact>
    <contact_backup>
      <last_name>Patricia D'Alessio</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ervin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Veronica Risinger</last_name>
      <phone>816-943-0770</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Tyndall</last_name>
    </contact>
    <contact_backup>
      <last_name>Penny Adams</last_name>
      <phone>814-283-0081</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Kivitz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mary Beyer</last_name>
      <phone>814-693-0694</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Cohen</last_name>
    </contact>
    <contact_backup>
      <last_name>Tri Nguyen</last_name>
      <phone>214-879-6737</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options/The SMART Clinic</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Giovanniello</last_name>
    </contact>
    <contact_backup>
      <last_name>Jennie Walker</last_name>
      <phone>801-352-9298</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

